NIOX Group Updates Share Capital and Total Voting Rights

Circassia Pharmaceuticals ( (GB:NIOX) ) has provided an announcement.

NIOX Group has confirmed that its issued share capital stands at 420,698,072 ordinary shares as of 30 April 2026, with each share carrying one voting right and no shares held in treasury. The company also reported that employees have recently exercised options over 284,618 ordinary shares under its share option schemes.

The newly issued shares have been admitted via existing block listings and rank pari passu with the company’s existing ordinary shares, preserving equal rights for all holders. The updated total voting rights figure provides shareholders with the reference denominator needed to assess and disclose any changes in their ownership stakes under FCA disclosure and transparency rules.

The most recent analyst rating on (GB:NIOX) stock is a Buy with a £86.00 price target. To see the full list of analyst forecasts on Circassia Pharmaceuticals stock, see the GB:NIOX Stock Forecast page.

Spark’s Take on NIOX Stock

According to Spark, TipRanks’ AI Analyst, NIOX is a Neutral.

The score is primarily supported by strong financial quality (growth, profitability, low debt, and solid cash generation). It is held back by bearish technical signals (price below major moving averages and negative MACD) and a high P/E that is only partly offset by the dividend yield.

To see Spark’s full report on NIOX stock, click here.

More about Circassia Pharmaceuticals

NIOX Group plc is a U.K.-listed healthcare company on AIM, focused on medical diagnostics for respiratory conditions through its NIOX-branded products. The business targets clinicians and healthcare systems that require accurate, non-invasive tools to support the management and monitoring of asthma and related lung diseases.

Average Trading Volume: 741,832

Technical Sentiment Signal: Buy

Current Market Cap: £285.9M

For an in-depth examination of NIOX stock, go to TipRanks’ Overview page.